In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or maybe the individuals are not able to tolerate the study drugs. For all stream cytometry experiments, ten,000 cells for every replicate were https://simoncfmeh.ssnblog.com/31205860/abbv-744-in-combination-with-immunotherapy-an-overview